Coronary Artery Disease, Hypertrophic Cardiomyopathy, Myocardial Bridging
Conditions
Brief summary
To investigate clinical characteristics and survival outcomes of patients with obstructive hypertrophic cardiomyopathy who underwent concomitant coronary artery bypass grafting during septal myectomy.
Detailed description
Surgical septal myectomy (SM) is an effective approach for treating patients with drug-refractory obstructive hypertrophic cardiomyopathy (HCM).However, numerous patients with HCM exhibit concurrent ischemic heart disease, including atherosclerotic coronary artery disease (CAD) and myocardial bridging (MB). Although patients with HCM have been known to possess diminished coronary flow reserve,additional CAD can worsen myocardial ischemia, contributing to an unfavorable prognosis.MB, although infrequent, may affect diastolic heart perfusion, leading to angina and even sudden death.Current guidelines recommend revascularization for ischemic heart disease caused by CAD and MB.However, the impact of concomitant coronary revascularization during HCM management remains unclear. In this study, we analyzed the clinical characteristics and surgical scenarios of patients who underwent concomitant coronary artery bypass grafting (CABG) during ventricular SM and investigated their prognosis. Patient clinical and survival data from 2009-2020 were retrospectively reviewed. The median follow-up period was 5.1 years. All-cause mortality was the primary endpoint.
Interventions
PROCEDURECABG during myectomy
To explore the effect of CABG during myectomy. No control group
Sponsors
Chinese Academy of Medical Sciences, Fuwai Hospital
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
8 Years to 90 Years
Healthy volunteers
No
Inclusion criteria
1. Clinical diagnosis of obstructive hypertrophic cardiomyopathy. 2. Undergo ventricular septal resection and cardiac bypass surgery at the same time.
Exclusion criteria
Incomplete surgical and follow-up data
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| all-cause mortality | through study completion, an average of 5 year | death because of any reason |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cardiac-related deaths and readmission | through study completion, an average of 5 year | deaths and readmission because of heart failure, stoke, and etc. |
Outcome results
None listed